Department of Pharmacy Practice & Pharmaceutical Sciences, University of Minnesota, Minneapolis, MN 55812, USA.
Bristol Myers Squibb, Lawrenceville, NJ 08540, USA.
Future Oncol. 2021 Aug;17(22):2940-2949. doi: 10.2217/fon-2021-0230. Epub 2021 Apr 14.
Chemotherapy (CT) alone was previously standard first-line (1L) therapy for metastatic non-small-cell lung cancer (NSCLC) but alternative treatments, including immunotherapy (I-O), are now available. In this retrospective study, adults with stage IV NSCLC who initiated 1L treatment between 1 August 2018 and 31 December 2019 and had ≥2 visits were identified in the Flatiron database. Patients were followed up until 30 June 2020. Baseline characteristics and treatment patterns were described by treatment group: CT, I-O + CT, I-O monotherapy and other. Approximately 20% of patients received 1L CT in the 2018-2019 timeframe studied; these patients tended to have squamous histology and low (≤49%) programmed death ligand-1 expression. A proportion of patients with metastatic NSCLC still receive 1L CT despite the availability and widespread use of I-O therapies.
化疗（CT）曾是转移性非小细胞肺癌（NSCLC）的标准一线（1L）治疗方法，但现在有其他替代治疗方法，包括免疫疗法（I-O）。在这项回顾性研究中，在 2018 年 8 月 1 日至 2019 年 12 月 31 日期间开始 1L 治疗且至少有 2 次就诊的 Flatiron 数据库中确定了患有 IV 期 NSCLC 的成年人。患者随访至 2020 年 6 月 30 日。按治疗组描述了基线特征和治疗模式：CT、I-O+CT、I-O 单药治疗和其他。在研究的 2018-2019 时间范围内，约有 20%的患者接受了 1L CT；这些患者往往具有鳞状组织学和低（≤49%）程序性死亡配体-1 表达。尽管免疫疗法的应用和广泛使用，但仍有一部分转移性 NSCLC 患者接受 1L CT。
